TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36164254

Group type: EXPERIMENTAL
Intervention: Paromomycin plus miltefosine (PM/MF) for 14 days
Number of subjects: 439

Group type: COMPARATOR
Intervention: Sodium stibogluconate plus paromomycin (SSG/PM) for 17 days
Number of subjects: 439
Study: 36164334

Group type: EXPERIMENTAL
Intervention: Ivermectin nanosuspension mucoadhesive nasal spray (two puffs per day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (saline nasal spray)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ivermectin group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 96
Study: 36164471

Group type: EXPERIMENTAL
Intervention: Self-reported Physical Functioning-10 items scale (PF-10) for OHCA survivors
Number of subjects: 287

Group type: COMPARATOR
Intervention: Self-reported Physical Functioning-10 items scale (PF-10) for STEMI controls
Number of subjects: 287
Study: 36164935

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg administered intravenously on day 1 of each 21-day cycle
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 51
Study: 36165038

Group type: EXPERIMENTAL
Intervention: Breast/Ovarian cancer syndrome
Number of subjects: 799

Group type: COMPARATOR
Intervention: Colorectal cancer
Number of subjects: 799
Study: 36165055

Group type: EXPERIMENTAL
Intervention: Mesalazine (Pentasa) treatment
Number of subjects: 93
Study: 36165137

Group type: EXPERIMENTAL
Intervention: Urinary UbA52 level in DM-NP group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Urinary UbA52 level
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Proteinuria level
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Urinary UbA52
Number of subjects: 90
Study: 36165742

Group type: EXPERIMENTAL
Intervention: Letrozole (with or without adjuncts)
Number of subjects: 6522
Study: 36165893

Group type: EXPERIMENTAL
Intervention: FAK inhibition (defactinib) in combination with stereotactic body radiotherapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of RT and FAK inhibition with checkpoint immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 0
Study: 36166279

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Real electroacupuncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 300
Study: 36166287

Group type: EXPERIMENTAL
Intervention: Care ally-assisted massage (3.5-hour training workshop, instructional DVD, printed treatment manual, three 30-minute at-home sessions weekly for 3 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist-treated massage (two 60-minute sessions tailored to individual pain experiences and treatments per week for 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 36166289

Group type: EXPERIMENTAL
Intervention: VR-based serious game (Jintronix system)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard care (Graded Repetitive Arm Supplementary Program kit)
Number of subjects: 51
Study: 36166340

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) with dual or triple antiplatelet therapy
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Vitamin K antagonists (warfarin) with corresponding strategies
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy
Number of subjects: 1080
Study: 36166648

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-driven digital health solution for self-management and clinical decision support
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wearable devices and validated patient-reported outcomes questionnaires
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Publicly available health and lifestyle data registries
Number of subjects: 10
Study: 36166658

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 36166849

Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Females in obese group
Number of subjects: 163
Study: 36167478

Group type: EXPERIMENTAL
Intervention: Regional catheters
Number of subjects: 158

Group type: COMPARATOR
Intervention: No regional analgesia
Number of subjects: 158
Study: 36167501

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study: 36167557

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with teleconsultations, early warning system, and digital patient record system.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard care with telemedicine component.
Number of subjects: 25
Study: 36167584

Group type: EXPERIMENTAL
Intervention: Interprofessional medication adherence intervention led by pharmacists, combining motivational interviews and feedback with electronic monitor (EM) drug assessment.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Patients who refused to participate in the intervention.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Female sex as a factor associated with non-participation.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Time from diabetes diagnosis as a factor associated with non-participation.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Age comparison between participants and non-participants.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Time from diabetes diagnosis comparison between participants and non-participants.
Number of subjects: 180
Study: 36167789

Group type: EXPERIMENTAL
Intervention: 30-15 intermittent fitness test
Number of subjects: 0
Study: 36167894

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HiDAC) with median dosage of 17.6 g/m (IQR 16.5-18.0)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Intermediate-dose cytarabine (IDAC)
Number of subjects: 642
Study: 36168113

Group type: EXPERIMENTAL
Intervention: HALT patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Patients' cognitive trajectory
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: HALT and WMH burden
Number of subjects: 153
Study: 36168454

Group type: EXPERIMENTAL
Intervention: Individual clinician feedback
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clinic-level feedback
Number of subjects: 26
Study: 36168552

Group type: EXPERIMENTAL
Intervention: Patients with thrombotic complications
Number of subjects: 904

Group type: COMPARATOR
Intervention: Patients without thrombotic complications
Number of subjects: 904
Study: 36168857

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - performed strengthening, stretching, and aerobic exercises for 30 minutes, 5 days a week.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rehabilitation Counselling Indications (RCI) - followed by both groups, 7 days a week.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group - Counselling Group (CG)
Number of subjects: 49
Study: 36168949

Group type: EXPERIMENTAL
Intervention: Operating Room Black Box (ORBB) system used during EVAR procedures
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Operating Room Black Box (ORBB) system used during PVI procedures
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Operating Room Black Box (ORBB) system used during procedures
Number of subjects: 22
Study: 36169967

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36169998

Group type: EXPERIMENTAL
Intervention: ADHD360 platform with serious game 'Pizza on Time' for approximately 30-45 minutes followed by 2-week behavior monitoring and 10 weeks of gameplay (2 times per week)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Behavior monitoring through the mADHD360 app after initial evaluation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Gameplay data analysis using state-of-the-art ML algorithms
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Initial neuropsychological evaluation
Number of subjects: 43
Study: 36170017

Group type: EXPERIMENTAL
Intervention: Early intensified treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36170124

Group type: EXPERIMENTAL
Intervention: Social mapping exercise indicating strength and direction of influence of members in their social networks.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Community- and peer-based PrEP sensitization and delivery interventions.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Social support for PrEP use.
Number of subjects: 33
Study: 36170256

Group type: EXPERIMENTAL
Intervention: Engage-PD telehealth coaching program
Number of subjects: 62
Study: 36170336

Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalization
Number of subjects: 104590
Study: 36170501

Group type: EXPERIMENTAL
Intervention: GPRC5D-targeted CAR T-cell therapy (MCARH109) at a maximum tolerated dose of 150×10^6 cells.
Number of subjects: 17
Study: 36170808

Group type: EXPERIMENTAL
Intervention: Phenotype C (ischemic phenotype)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Phenotype B (edema phenotype)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both phenotypes B and C
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Phenotype B
Number of subjects: 122
Study: 36170815

Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NADPH oxidase inhibitor apocynin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protein restriction cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FMD cycles in a small group of AD patients
Number of subjects: 0
Study: 36171016

Group type: EXPERIMENTAL
Intervention: Negative subscales of the Self-Compassion Scale (SCS) and daytime sleepiness
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Psychological interventions focused on reducing negative self-compassion and improving sleep behavior
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Reducing diabetes-related distress (DRD)
Number of subjects: 467
Study: 36171082

Group type: EXPERIMENTAL
Intervention: Patients with postinfective bowel dysfunction (PI-BD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: High fibre diets (prebiotic effect)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Age-matched and sex-matched controls
Number of subjects: 155
Study: 36171104

Group type: EXPERIMENTAL
Intervention: Longitudinal Expanded Disability Status Scale (EDSS) scores modeled by latent class growth analysis (LCGA)
Number of subjects: 3613
Study: 36171475

Group type: EXPERIMENTAL
Intervention: Dual-mutant virus (A(H1N1)pdm09 with NA-H275Y and PA-I38T mutations)
Number of subjects: 0
Study: 36171508

Group type: EXPERIMENTAL
Intervention: Low SVCF < 55 ml/kg/min
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: High ACA-RI > 0.75
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined use of low SVCF < 55 ml/kg/min and ACA-RI > 0.75
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Low SVCF and high ACA-RI
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combined metrics using cut-off value of < 41 ml/kg/min for SVCF and > 0.85 for ACA-RI
Number of subjects: 132
Study: 36171598

Group type: EXPERIMENTAL
Intervention: BATT score (prehospital)
Number of subjects: 13222

Group type: EXPERIMENTAL
Intervention: ABC score (prehospital)
Number of subjects: 13222

Group type: EXPERIMENTAL
Intervention: Shock Index (SI) (prehospital)
Number of subjects: 13222

Group type: EXPERIMENTAL
Intervention: TASH score (at hospital admission)
Number of subjects: 13222

Group type: EXPERIMENTAL
Intervention: BATT score
Number of subjects: 13222

Group type: EXPERIMENTAL
Intervention: Massive transfusion (MT)
Number of subjects: 13222
Study: 36171964

Group type: EXPERIMENTAL
Intervention: Khanya intervention (Life Steps adherence counseling, motivational interviewing, behavioral activation, and relapse prevention including mindfulness-based relapse prevention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Khanya intervention
Number of subjects: 0
Study: 36171985

Group type: EXPERIMENTAL
Intervention: Presence of Hi, Mcat, or HRV in sputum samples during exacerbation episodes
Number of subjects: 197

Group type: COMPARATOR
Intervention: Sputum samples collected during stable COPD and AECOPD
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Mean yearly AECOPD incidence rate
Number of subjects: 197
Study: 36172030

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) with alteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline systolic blood pressure (trichotomized as high (141-185 mmHg), middle (121-140 mmHg), and low (91-120 mmHg))
Number of subjects: 0
Study: 36172135

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 and Placebo
Number of subjects: 2247
Study: 36172138

Group type: EXPERIMENTAL
Intervention: Infliximab (single dose infusion)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1033
Study: 36172173

Group type: EXPERIMENTAL
Intervention: Niraparib maintenance
Number of subjects: 3
Study: 36172517

Group type: EXPERIMENTAL
Intervention: Swedish quality register for systematic data collection from patients receiving treatment for gambling disorder.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality register data collection
Number of subjects: 0
Study: 36172535

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 317

Group type: COMPARATOR
Intervention: No Physiotherapy
Number of subjects: 317
Study: 36172577

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI with complete revascularization (PCI-CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCI with incomplete revascularization (PCI-IR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 36172964

Group type: EXPERIMENTAL
Intervention: Spironolactone prescription in ideal patients
Number of subjects: 2122

Group type: EXPERIMENTAL
Intervention: Spironolactone prescription in contraindicated patients
Number of subjects: 2122
Study: 36173242

Group type: EXPERIMENTAL
Intervention: EpiSmart epi-on crosslinking (riboflavin/sodium iodide and pulsed UVA exposure)
Number of subjects: 2228
Study: 36173261

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) consisting of 3 sets of 10 repetitions at 60% of 1 repetition maximum (1RM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 20
Study: 36173399

Group type: EXPERIMENTAL
Intervention: Cascade testing in FH families with a monogenic etiology
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cascade testing in FH families without a monogenic etiology
Number of subjects: 52
Study: 36173816

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36173829

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory diet (higher E-DII score)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory diet (higher E-DII score) among European Americans
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (5 points lower E-DII score)
Number of subjects: 207
Study: 36174113

Group type: EXPERIMENTAL
Intervention: Letrozole/Abemaciclib
Number of subjects: 30
Study: 36174135

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 0
Study: 36174389

Group type: EXPERIMENTAL
Intervention: Non-invasive finger blood pressure (BP)
Number of subjects: 33
Study: 36174613

Group type: EXPERIMENTAL
Intervention: Veno-arterial (VA)-ECMO
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Veno-venous (VV)-ECMO
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (eCPR)
Number of subjects: 391

Group type: COMPARATOR
Intervention: VV-ECMO
Number of subjects: 391

Group type: COMPARATOR
Intervention: VA-ECMO
Number of subjects: 391
Study: 36174774

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study: 36175036

Group type: EXPERIMENTAL
Intervention: lerapolturev
Number of subjects: 12
Study: 36175060

Group type: EXPERIMENTAL
Intervention: Right-sided greater splanchnic nerve (GSN) ablation
Number of subjects: 11
Study: 36175098

Group type: EXPERIMENTAL
Intervention: Acute management interventions including protective equipment and decontamination capabilities
Number of subjects: 0
Study: 36175253

Group type: EXPERIMENTAL
Intervention: Low body weight (<60 kg)
Number of subjects: 11821

Group type: EXPERIMENTAL
Intervention: High body weight (>100 kg)
Number of subjects: 11821

Group type: COMPARATOR
Intervention: Middle body weight (60 to 100 kg)
Number of subjects: 11821
Study: 36175821

Group type: EXPERIMENTAL
Intervention: 1% atropine weekly tapered to 0.01% atropine daily at 6 months
Number of subjects: 207

Group type: COMPARATOR
Intervention: 0.01% atropine daily for 1 year
Number of subjects: 207
Study: 36175848

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) at 1.0 - 1.5 mA for 20 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS (initial 30-second ramp up to 1.5 mA followed by a 30-second ramp down)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adverse events survey, Box and Blocks Test (BBT) motor assessment, setup ease/comfort survey
Number of subjects: 10
Study: 36175864

Group type: EXPERIMENTAL
Intervention: TF-CBT with high-intensity therapist training
Number of subjects: 1240

Group type: COMPARATOR
Intervention: TF-CBT with low therapist and leadership training
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 1240
Study: 36175948

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antimicrobial therapy for more than 72 hours
Number of subjects: 254

Group type: COMPARATOR
Intervention: Narrow-spectrum antimicrobial therapy (less than 72 hours)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Cerebrovascular comorbidity on ICU admission
Number of subjects: 254
Study: 36175978

Group type: EXPERIMENTAL
Intervention: Eye Scan Ultrasound System (ESUS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lens Opacity Classification System III (LOCS III, comparator)
Number of subjects: 50
Study: 36175988

Group type: EXPERIMENTAL
Intervention: Autologous CD7 CAR T-cells
Number of subjects: 1
Study: 36176043

Group type: EXPERIMENTAL
Intervention: Low-dose-rate brachytherapy (LDR-BT)
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1241
Study: 36176639

Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin D
Number of subjects: 144
Study: 36177053

Group type: EXPERIMENTAL
Intervention: Preoperative robotic radiosurgery (prRS) - single 21 Gy fraction
Number of subjects: 70
Study: 36177306

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) training for 8 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 69
Study: 36177676

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 55
Study: 36177835

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 10000
Study: 36177910

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 2737
Study: 36177913

Group type: EXPERIMENTAL
Intervention: CCRT-durvalumab
Number of subjects: 84

Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 84
Study: 36178036

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36178134

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36178485

Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (ongoing treatment with evolocumab 140 mg, n=632, 38.1% of total)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (newly treated within 30 days before baseline visit)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (ongoing treatment)
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (both groups)
Number of subjects: 1659

Group type: COMPARATOR
Intervention: Non-receivers
Number of subjects: 1659
Study: 36178583

Group type: EXPERIMENTAL
Intervention: Etanercept treatment adherence after 1 year
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Etanercept treatment adherence after 7 years
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Mean change in BASDAI score for adherent patients at 1 year
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Mean change in BASFI score for adherent patients at 1 year
Number of subjects: 763
Study: 36178584

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg administered subcutaneously (SC) at weeks 0, 4, and every 12 weeks thereafter
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study: 36178715

Group type: EXPERIMENTAL
Intervention: Automated Story Recall Task (ASRT)
Number of subjects: 200
Study: 36179090

Group type: EXPERIMENTAL
Intervention: Wearable sensors during 1 week of unsupervised daily-living monitoring
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: In-home off-medication testing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Self-report questionnaires
Number of subjects: 28

Group type: COMPARATOR
Intervention: In-home on-medication testing
Number of subjects: 28
Study: 36179255

Group type: EXPERIMENTAL
Intervention: NOT-rule 1
Number of subjects: 4804

Group type: EXPERIMENTAL
Intervention: NOT-rule 2
Number of subjects: 4804

Group type: EXPERIMENTAL
Intervention: NOT-rule 3
Number of subjects: 4804

Group type: EXPERIMENTAL
Intervention: NOT-rules overall
Number of subjects: 4804
Study: 36179488

Group type: EXPERIMENTAL
Intervention: Dose and volume de-escalated intensity-modulated radiation therapy (IMRT) after two cycles of induction chemotherapy with docetaxel 60 mg/m².
Number of subjects: 131